Actinium Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 2/4

Actinium Pharmaceuticals CEO'su Sandesh Seth, Jun2017 tarihinde atandı, in görev süresi 7.42 yıldır. in toplam yıllık tazminatı $ 4.70M olup, şirket hissesi ve opsiyonları dahil olmak üzere 15% maaş ve 85% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.017% ine doğrudan sahiptir ve bu hisseler € 7.60K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.2 yıl ve 11 yıldır.

Anahtar bilgiler

Sandesh Seth

İcra Kurulu Başkanı

US$4.7m

Toplam tazminat

CEO maaş yüzdesi	15.0%
CEO görev süresi	7.4yrs
CEO sahipliği	0.02%
Yönetim ortalama görev süresi	3.2yrs
Yönetim Kurulu ortalama görev süresi	11yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Sandesh Seth'un ücretlendirmesi Actinium Pharmaceuticals'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$41m
Jun 30 2024	n/a	n/a	-US$43m
Mar 31 2024	n/a	n/a	-US$46m
Dec 31 2023	US$5m	US$705k	-US$49m
Sep 30 2023	n/a	n/a	-US$50m
Jun 30 2023	n/a	n/a	-US$46m
Mar 31 2023	n/a	n/a	-US$39m
Dec 31 2022	US$4m	US$665k	-US$33m
Sep 30 2022	n/a	n/a	-US$30m
Jun 30 2022	n/a	n/a	-US$27m
Mar 31 2022	n/a	n/a	-US$25m
Dec 31 2021	US$2m	US$615k	-US$25m
Sep 30 2021	n/a	n/a	-US$23m
Jun 30 2021	n/a	n/a	-US$22m
Mar 31 2021	n/a	n/a	-US$22m
Dec 31 2020	US$2m	US$578k	-US$22m
Sep 30 2020	n/a	n/a	-US$20m
Jun 30 2020	n/a	n/a	-US$21m
Mar 31 2020	n/a	n/a	-US$22m
Dec 31 2019	US$1m	US$561k	-US$22m
Sep 30 2019	n/a	n/a	-US$24m
Jun 30 2019	n/a	n/a	-US$23m
Mar 31 2019	n/a	n/a	-US$23m
Dec 31 2018	US$1m	US$545k	-US$24m
Sep 30 2018	n/a	n/a	-US$22m
Jun 30 2018	n/a	n/a	-US$23m
Mar 31 2018	n/a	n/a	-US$25m
Dec 31 2017	US$306k	US$306k	-US$27m

Tazminat ve Piyasa: Sandesh 'nin toplam tazminatı ($USD 4.70M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 471.14K ).

Tazminat ve Kazançlar: Sandesh şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Sandesh Seth (60 yo)

7.4yrs

Görev süresi

US$4,704,999

Tazminat

Mr. Sandesh C. Seth, M.S., MBA has been Chief Executive Officer of Actinium Pharmaceuticals, Inc. since June 5, 2017. Mr. Seth serves as the Head of Healthcare Investment Banking at Laidlaw & Company (UK)...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Sandesh Seth	Chairman & CEO	7.4yrs	US$4.70m	0.017% € 7.6k
Steven O'Loughlin	CFO & Corporate Secretary	7.5yrs	US$1.49m	0.0038% € 1.7k
Paul Diamond	Vice President of Patent & Legal Counsel	3.2yrs	Veri yok	Veri yok
Avinash Desai	Chief Medical Officer	4yrs	Veri yok	Veri yok
Jenny Hsieh	Chief Strategy Officer	2.1yrs	Veri yok	Veri yok
Sunitha Lakshminarayanan	Senior VP	2.1yrs	Veri yok	Veri yok
Caroline Yarbrough	Chief Commercial Officer	2yrs	Veri yok	Veri yok
Lynn Bodarky	Chief Business Officer	less than a year	Veri yok	Veri yok
J. Simeon	Executive Director of Quality Assurance	8.2yrs	Veri yok	Veri yok
Madhuri Vusirikala	Vice President of Clinical Development BMT & Cellular Therapy	no data	Veri yok	Veri yok

3.2yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim: 7AY1 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Sandesh Seth	Chairman & CEO	12.7yrs	US$4.70m	0.017% € 7.6k
Richard Steinhart	Independent Director	11yrs	US$313.00k	0.0010% € 444.8
David Scheinberg	Member of Clinical Advisory Board	no data	Veri yok	Veri yok
Hagop M. Kantarjian	Member of Clinical Advisory Board	no data	Veri yok	Veri yok
Richard Wahl	Member of Clinical Advisory Board	no data	Veri yok	Veri yok
Ajit S. Shetty	Independent Director	7.7yrs	US$308.50k	0.0024% € 1.1k
C. Nicholson	Lead Independent Director	16.8yrs	US$313.00k	0.0011% € 471.2
Joseph Jurcic	Chairman of Clinical Advisory Board	no data	Veri yok	Veri yok
Elihu Estey	Member of Clinical Advisory Board	no data	Veri yok	Veri yok
John Pagel	Chairman of Scientific Advisory Board & Member of Clinical Advisory Board	no data	Veri yok	Veri yok
Alexander Perl	Member of Clinical Advisory Board	no data	Veri yok	Veri yok
Sergio Giralt	Member of Scientific Advisory Board	10.4yrs	Veri yok	Veri yok

11.0yrs

Ortalama Görev Süresi

68yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 7AY1 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 11 yıldır).

Actinium Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Actinium Pharmaceuticals, Inc., Annual General Meeting, Nov 27, 2024

Actinium Pharmaceuticals, Inc. Appoints June Almenoff to its Board

Actinium Pharmaceuticals, Inc., Annual General Meeting, Nov 30, 2023

Actinium Pharmaceuticals, Inc. Appoints Lynn Bodarky as Chief Business Officer

Actinium Pharmaceuticals, Inc., Annual General Meeting, Dec 08, 2022

Insufficient new directors

Recent updates

Actinium Pharmaceuticals, Inc., Annual General Meeting, Nov 27, 2024

Actinium Pharmaceuticals, Inc. Appoints June Almenoff to its Board

No longer forecast to breakeven

Actinium Pharmaceuticals, Inc. Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S

Actinium Pharmaceuticals, Inc. Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease

Actinium Pharmaceuticals, Inc.(NYSEAM:ATNM) dropped from Russell Small Cap Comp Value Index

Actinium Pharmaceuticals, Inc. Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial

Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in Tp53 Positive Patients At the Eha 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phase 3 Sierra Trial

Actinium Pharmaceuticals, Inc. Announces KOL Webinar to Highlight Recently Announced Iomab-ACT Trial with Leading FDA Approved Commercial CAR T-Cell Therapy Being Led by the University of Texas Southwestern

Forecast to breakeven in 2026

Forecast breakeven date pushed back to 2026

Actinium Pharmaceuticals, Inc. Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting

Actinium Pharmaceuticals, Inc. Announces Iomab-B Phase 3 Sierra Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation At the 50Th European Bone Marrow Transplant Annual Meeting

Forecast breakeven date pushed back to 2026

Actinium Pharmaceuticals Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with FDA Approved Commercial CAR T-Cell Therapy

Actinium Pharmaceuticals, Inc. Announces Results from the Phase 3 SIERRA Trial of Iomab-B Were Presents in an Oral Presentation At the 65th Annual American Society of Hematology Meeting & Exposition

Actinium Pharmaceuticals, Inc., Annual General Meeting, Nov 30, 2023

Actinium Pharmaceuticals, Inc. Appoints Lynn Bodarky as Chief Business Officer

Actinium Pharmaceuticals, Inc. Announces Oral Presentation at ASH Annual Meeting

New major risk - Share price stability

National Institutes of Health Awards Actinium A Small Business Technology Transfer Grant Extension to Actinium Pharmaceuticals, Inc

National Institutes of Health Awards Actinium A Small Business Technology Transfer Grant Extension to Actinium Pharmaceuticals, Inc

Forecast to breakeven in 2025

Actinium Pharmaceuticals, Inc. to Present Full Results from Pivotal Phase 3 Iomab-B SIERRA Trial on Investor Call Following the Late-Breaker Presentation at the 2023 Transplantation & Cellular Therapy Tandem Meetings

Forecast to breakeven in 2025

Actinium Highlights Survival Data in Relapsed/Refractory Aml Patients with Prior Venetoclax Treatment And/Or with A Tp53 Mutation from the Actimab-A Clag-M Combination Trial Oral Presentation At Ash

Actinium Pharmaceuticals, Inc., Annual General Meeting, Dec 08, 2022

Forecast to breakeven in 2024

Insufficient new directors

Actinium Pharmaceuticals, Inc. Provides Update on Iomab-B and the Pivotal Phase 3 Trial

Actinium Pharmaceuticals, Inc. Announces Positive Top-Line Results from Pivotal Phase 3 SIERRA Trial of Iomab-B in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia

Actinium Pharmaceuticals, Inc. Announces Executive Changes

Actinium Pharmaceuticals, Inc. Announces Executive Appointments

Actinium Pharmaceuticals, Inc. Provides Topline Results for the Pivotal Phase 3 Sierra Trial for Iomab-B

No longer forecast to breakeven

Insufficient new directors

Actinium Pharmaceuticals, Inc. Highlights Data from Full Patient Enrollment in the Pivotal Phase 3 SIERRA Trial of Iomab-B Was Presented in an Oral Presentation At the Upcoming Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR

Actinium Pharmaceuticals, Inc. Highlights Potent Anti-Tumor Activity of a HER3 Targeted Radiotherapy at AACR

Forecast to breakeven in 2024

Forecast to breakeven in 2023

Actinium Pharmaceuticals, Inc. Announces 72% MRD Negativity Rate in the Recently Completed Phase 1 Study of Actimab-A in Combination with Clag-M for Patients with Relapsed or Refractory AML

Actinium Pharmaceuticals, Inc. Announces Positive Data from Fully Enrolled Pivotal Phase 3 SIERRA Trial of Iomab-B Presents at 63rd American Society of Hematology Annual Meeting and Exposition

Forecast to breakeven in 2023

Chief Medical Officer Mark Berger has left the company

Chief Medical Officer Mark Berger has left the company

Actinium Pharmaceuticals, Inc. Completes Enrollment in the Pivotal Phase 3 SIERRA Trial of Iomab-B

Actinium Pharmaceuticals, Inc. Announces Safety Data from Phase 3 SIERRA Trial of Iomab-B

Actinium Pharmaceuticals, Inc. Announces Several Presentations from the Phase 3 SIERRA Study of Iomab-B at the SNMMI 2021 Virtual Annual Meeting

Actinium to Highlight Expansion of Targeted Conditioning Portfolio at AACR with Next-Generation Actinium-225-Based CD45 Targeting ARC

Actinium Pharmaceuticals, Inc. Appoints Mark Kubik as Chief Business Officer

Actinium and Astellas Announce Research Collaboration Focused on Novel Actinium-225 Based Targeted Radiotherapies

New 90-day low: €6.75

Actinium Announces Successful Pre-Planned Ad Hoc Interim Analysis of Phase 3 SIERRA Trial

Actinium Pharmaceuticals, Inc. Reports 67% Overall Response Rate in First Cohort in Actimab-A Venetoclax Combination Trial in Relapsed and Refractory AML at ASH

Actinium Pharmaceuticals, Inc. Appoints Avinash Desai as Executive Vice President of Clinical Development, Operations and Medical Affairs

New 90-day high: €10.30

Actinium Pharmaceuticals, Inc. Announces 100% Remission Rate Reported in Third Dose Cohort of Actimab-A CLAG-M Phase 1 Combination Trial in Patients with Relapsed or Refractory AML

Actinium Pharmaceuticals, Inc. Announces Clinical Trial Site Expansion in Its Multi-Center Phase 1/2 Actimab-A Venetoclax Combination Trial

Actinium Pharmaceuticals Successfully Completes First Dosing Cohort in the Phase 1 Study of Actimab-A and Venetoclax Combination Therapy in Relapsed/Refractory Aml Patients

New 90-day low - €6.59

Actinium Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $24.997873 million.

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri